Pharmacovigilance: in-house or outsource?

Building the future: Recruiting for foundation models, GenAI and LLMs in biology

Sam Francis, Associate Director at BioTalent, on the skills and talent strategies reshaping foundation model, GenAI and LLM hiring in biology.

From batch to bioreactor: How Industry 4.0 is reinventing CDMO flexibility

Why flexibility is the new CDMO differentiator, and how digital twins, real-time analytics and AI are reshaping biomanufacturing talent needs.

The impact of Generative AI on life sciences professionals

Nicholas Boyle polled his network on generative AI's day-to-day impact here's what life sciences professionals said.

Why the seed funding slowdown is a talent problem, not just a funding one.

Seed funding in life sciences is down 44% year on year, and BioTalent explains why that funding gap points to a hiring gap a few years out.

Workforce Engineering: The Future of Biopharmaceutical Manufacturing

Jason Beckwith's new publication introduces workforce engineering, treating workforce capability as a measurable production asset alongside capital and…

What AI adoption means for your scientific talent pipeline

BioTalent explores what AI adoption really means for scientific hiring, and why developing future talent matters more than debating whether AI will replace…

The real cost of a misaligned hire in biopharma and how to reduce the risk

A look at the true cost of a misaligned senior hire in biopharma, and how an evidence led approach to leadership selection can reduce that risk.

The execution gap: why leadership capability is the most underestimated risk in life sciences

Why leadership capability, not scientific quality, is the most underestimated risk in life sciences and how Talent Science™ and BioX address it.

The workforce of tomorrow: are you building for it?

Why workforce planning built on five-year-old assumptions no longer works, and how Talent Science™ gives leaders a quantitative view of what's next.

Leadership across the drug development lifecycle: why one hiring approach doesn't fit all

How leadership needs change across each phase of drug development, and why BioX matches executive hires to the organisation's actual growth stage.

The skills powering biomanufacturing's next revolution

Why the real bottleneck in biomanufacturing's AI transformation is workforce skills, not technology: insights from Dr Jason Beckwith.

The biotech market is back. The early-stage ecosystem isn't

BioTalent CEO James Cox analyses 14 months of biopharma financing data, revealing a widening gap between late-stage capital and early-stage funding.